229 related articles for article (PubMed ID: 21151387)
21. Structural basis of the multispecificity demonstrated by 17beta-hydroxysteroid dehydrogenase types 1 and 5.
Lin SX; Shi R; Qiu W; Azzi A; Zhu DW; Dabbagh HA; Zhou M
Mol Cell Endocrinol; 2006 Mar; 248(1-2):38-46. PubMed ID: 16480815
[TBL] [Abstract][Full Text] [Related]
22. AKR1C3 as a target in castrate resistant prostate cancer.
Adeniji AO; Chen M; Penning TM
J Steroid Biochem Mol Biol; 2013 Sep; 137():136-49. PubMed ID: 23748150
[TBL] [Abstract][Full Text] [Related]
23. Aldo-keto reductase 1C3 may be a new radioresistance marker in non-small-cell lung cancer.
Xie L; Yu J; Guo W; Wei L; Liu Y; Wang X; Song X
Cancer Gene Ther; 2013 Apr; 20(4):260-6. PubMed ID: 23519145
[TBL] [Abstract][Full Text] [Related]
24. A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells.
Jamieson SM; Gu Y; Manesh DM; El-Hoss J; Jing D; Mackenzie KL; Guise CP; Foehrenbacher A; Pullen SM; Benito J; Smaill JB; Patterson AV; Mulaw MA; Konopleva M; Bohlander SK; Lock RB; Wilson WR
Biochem Pharmacol; 2014 Mar; 88(1):36-45. PubMed ID: 24434189
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of aldo-keto reductase 1C3 overcomes gemcitabine/cisplatin resistance in bladder cancer.
Himura R; Kawano S; Nagata Y; Kawai M; Ota A; Kudo Y; Yoshino Y; Fujimoto N; Miyamoto H; Endo S; Ikari A
Chem Biol Interact; 2024 Jan; 388():110840. PubMed ID: 38122923
[TBL] [Abstract][Full Text] [Related]
26. AKR1C3 (type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase): Roles in malignancy and endocrine disorders.
Penning TM
Mol Cell Endocrinol; 2019 Jun; 489():82-91. PubMed ID: 30012349
[TBL] [Abstract][Full Text] [Related]
27. Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells.
Doig CL; Battaglia S; Khanim FL; Bunce CM; Campbell MJ
J Steroid Biochem Mol Biol; 2016 Jan; 155(Pt A):47-55. PubMed ID: 26429394
[TBL] [Abstract][Full Text] [Related]
28. Structure of AKR1C3 with 3-phenoxybenzoic acid bound.
Jackson VJ; Yosaatmadja Y; Flanagan JU; Squire CJ
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2012 Apr; 68(Pt 4):409-13. PubMed ID: 22505408
[TBL] [Abstract][Full Text] [Related]
29. Screening baccharin analogs as selective inhibitors against type 5 17β-hydroxysteroid dehydrogenase (AKR1C3).
Zang T; Verma K; Chen M; Jin Y; Trippier PC; Penning TM
Chem Biol Interact; 2015 Jun; 234():339-48. PubMed ID: 25555457
[TBL] [Abstract][Full Text] [Related]
30. Aldo-keto reductase 1C3 is expressed in differentiated human epidermis, affects keratinocyte differentiation, and is upregulated in atopic dermatitis.
Mantel A; Carpenter-Mendini AB; Vanbuskirk JB; De Benedetto A; Beck LA; Pentland AP
J Invest Dermatol; 2012 Apr; 132(4):1103-10. PubMed ID: 22170488
[TBL] [Abstract][Full Text] [Related]
31. Identification of a principal mRNA species for human 3alpha-hydroxysteroid dehydrogenase isoform (AKR1C3) that exhibits high prostaglandin D2 11-ketoreductase activity.
Matsuura K; Shiraishi H; Hara A; Sato K; Deyashiki Y; Ninomiya M; Sakai S
J Biochem; 1998 Nov; 124(5):940-6. PubMed ID: 9792917
[TBL] [Abstract][Full Text] [Related]
32. Crystal structures of three classes of non-steroidal anti-inflammatory drugs in complex with aldo-keto reductase 1C3.
Flanagan JU; Yosaatmadja Y; Teague RM; Chai MZ; Turnbull AP; Squire CJ
PLoS One; 2012; 7(8):e43965. PubMed ID: 22937138
[TBL] [Abstract][Full Text] [Related]
33. Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma.
Lewis MJ; Wiebe JP; Heathcote JG
BMC Cancer; 2004 Jun; 4():27. PubMed ID: 15212687
[TBL] [Abstract][Full Text] [Related]
34. Modulated expression of genes encoding estrogen metabolizing enzymes by G1-phase cyclin-dependent kinases 6 and 4 in human breast cancer cells.
Jia Y; Domenico J; Swasey C; Wang M; Gelfand EW; Lucas JJ
PLoS One; 2014; 9(5):e97448. PubMed ID: 24848372
[TBL] [Abstract][Full Text] [Related]
35. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
[TBL] [Abstract][Full Text] [Related]
36. Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approach.
Pippione AC; Giraudo A; Bonanni D; Carnovale IM; Marini E; Cena C; Costale A; Zonari D; Pors K; Sadiq M; Boschi D; Oliaro-Bosso S; Lolli ML
Eur J Med Chem; 2017 Oct; 139():936-946. PubMed ID: 28881288
[TBL] [Abstract][Full Text] [Related]
37. AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids.
Skarydová L; Zivná L; Xiong G; Maser E; Wsól V
Chem Biol Interact; 2009 Mar; 178(1-3):138-44. PubMed ID: 19007764
[TBL] [Abstract][Full Text] [Related]
38. Human dehydrogenase/reductase SDR family member 11 (DHRS11) and aldo-keto reductase 1C isoforms in comparison: Substrate and reaction specificity in the reduction of 11-keto-C
Endo S; Morikawa Y; Kudo Y; Suenami K; Matsunaga T; Ikari A; Hara A
J Steroid Biochem Mol Biol; 2020 May; 199():105586. PubMed ID: 31926269
[TBL] [Abstract][Full Text] [Related]
39. The Steroidogenic Enzyme AKR1C3 Regulates Stability of the Ubiquitin Ligase Siah2 in Prostate Cancer Cells.
Fan L; Peng G; Hussain A; Fazli L; Guns E; Gleave M; Qi J
J Biol Chem; 2015 Aug; 290(34):20865-20879. PubMed ID: 26160177
[TBL] [Abstract][Full Text] [Related]
40. Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progression.
Dozmorov MG; Azzarello JT; Wren JD; Fung KM; Yang Q; Davis JS; Hurst RE; Culkin DJ; Penning TM; Lin HK
BMC Cancer; 2010 Dec; 10():672. PubMed ID: 21134280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
